Novel Biomarkers of Diabetic Kidney Disease
| datacite.rights | http://purl.org/coar/access_right/c_abf2 | spa |
| dc.contributor.author | Rico-Fontalvo, Jorge | |
| dc.contributor.author | Aroca-Martínez, Gustavo | |
| dc.contributor.author | Daza-Arnedo, Rodrigo | |
| dc.contributor.author | Cabrales, José | |
| dc.contributor.author | Rodríguez-Yánez, Tomás | |
| dc.contributor.author | Cardona-Blanco, María | |
| dc.contributor.author | Montejo-Hernández, Juan | |
| dc.contributor.author | Rodelo Barrios, Dairo | |
| dc.contributor.author | Patiño-Patiño, Jhonny | |
| dc.contributor.author | Osorio Rodríguez, Elber | |
| dc.date.accessioned | 2023-03-31T19:55:19Z | |
| dc.date.available | 2023-03-31T19:55:19Z | |
| dc.date.issued | 2023 | |
| dc.description.abstract | Diabetic kidney disease (DKD) is a highly prevalent condition worldwide. It represents one of the most common complications arising from diabetes mellitus (DM) and is the leading cause of end-stage kidney disease (ESKD). Its development involves three fundamental components: the hemodynamic, metabolic, and inflammatory axes. Clinically, persistent albuminuria in association with a progressive decline in glomerular filtration rate (GFR) defines this disease. However, as these alterations are not specific to DKD, there is a need to discuss novel biomarkers arising from its pathogenesis which may aid in the diagnosis, follow-up, therapeutic response, and prognosis of the disease. | spa |
| dc.format.mimetype | spa | |
| dc.identifier.citation | Rico-Fontalvo, J.; Aroca-Martínez, G.; Daza-Arnedo, R.; Cabrales, J.; Rodríguez-Yanez, T.; Cardona-Blanco, M.; Montejo- Hernández, J.; Rodelo Barrios, D.; Patiño-Patiño, J.; Osorio Rodríguez, E. Novel Biomarkers of Diabetic Kidney Disease. Biomolecules 2023, 13, 633. https://doi.org/10.3390/ biom13040633 | spa |
| dc.identifier.doi | https://doi.org/10.3390/biom13040633 | |
| dc.identifier.issn | 2218273X | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/12149 | |
| dc.identifier.url | https://www.mdpi.com/2218-273X/13/4/633 | |
| dc.language.iso | eng | spa |
| dc.publisher | MDPI | spa |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.source | Biomolecules | eng |
| dc.source | Vol. 13 No. 4 Año 2023 | |
| dc.subject | Biomarkers | eng |
| dc.subject | Diabetic kidney disease | eng |
| dc.subject | Pathogenesis | eng |
| dc.subject | Diabetes mellitus | eng |
| dc.title | Novel Biomarkers of Diabetic Kidney Disease | eng |
| dc.type.driver | info:eu-repo/semantics/article | spa |
| dc.type.spa | Artículo científico | spa |
| dcterms.references | Rico-Fontalvo, J.; Aroca, G.; Cabrales, J.; Daza-Arnedo, R.; Yánez-Rodríguez, T.; Martínez-Ávila, M.C.; Uparella-Gulfo, I.; Raad-Sarabia, M. Molecular mechanisms of diabetic kidney disease. Int. J. Mol. Sci. 2022, 23, 8668. | eng |
| dcterms.references | Jung, C.Y.; Yoo, T.H. Pathophysiologic mechanisms and potential biomarkers in diabetic kidney disease. Diabetes Metab. J. 2022, 46, 181–197. | eng |
| dcterms.references | Jorge, R.F.; Rodrigo, D.A.; Tomas, R.Y.; Maria Cristina, M.A.; Jose, C.; Maria Ximena, C.B.; Amilkar, A.-H.; Isabella, U.-G.; Oscar, V. Inflammation and diabetic kidney disease: New perspectives. J. Biomed. Res. Environ. Sci. 2022, 3, 779–786. | eng |
| dcterms.references | Rico Fontalvo, J.E.; Vázquez Jiménez, L.C.; Rodríguez Yánez, T.; Daza Arnedo, R.; Raad, M.; Montejo Hernandez, J.D.; Abuabara- Franco, E. Diabetic kidney disease: Updating. Rev. Andal. Fac. Med. 2022, 55, 86–98. | eng |
| dcterms.references | Peña, M.J.; Mischak, H.; Heerspink, H.J.L. Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease. Diabetologia 2016, 59, 1819–1831. | eng |
| dcterms.references | Daza-Arnedo, R.; Rico-Fontalvo, J.E.; Pájaro-Galvis, N.; Leal-Martínez, V.; Abuabara-Franco, E.; Raad-Sarabia, M.; Montejo- Hernández, J.; Cardona-Blanco, M.; Cabrales-Juan, J.; Uparella-Gulfo, I.; et al. Dipeptidyl peptidase-4 inhibitors and diabetic kidney disease: A narrative review. Kidney Med. 2021, 3, 1065–1073. | eng |
| dcterms.references | Kidney Disease: Improving Global Outcomes (KDIGO) DiabetesWork Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022, 102 (Suppl. 5), S1–S127. | eng |
| dcterms.references | Fontalvo, J.E.R. Clinical practice guidelines for diabetic kidney disease. Rev. Colomb. Nefrol. 2021, 8, e561. | eng |
| dcterms.references | Looker, H.C.; Mauer, M.; Nelson, R.G. Role of kidney biopsies for biomarker discovery in diabetic kidney disease. Adv. Chronic Kidney Dis. 2018, 25, 192–201. | eng |
| dcterms.references | Colhoun, H.M.; Marcovecchio, M.L. Biomarkers of diabetic kidney disease. Diabetologia 2018, 61, 996–1011. | eng |
| dcterms.references | Pereira, P.R.; Carrageta, D.F.; Oliveira, P.F.; Rodrigues, A.; Alves, M.G.; Monteiro, M.P. Metabolomics as a tool for the early diagnosis and prognosis of diabetic kidney disease. Med. Res. Rev. 2022, 42, 1518–1544. | eng |
| dcterms.references | Nowak, N.; Skupien, J.; Niewczas, M.A.; Yamanouchi, M.; Major, M.; Croall, S.; Smiles, A.; Warram, J.; Bonventre, J.; Krolewski, A. Increased plasma kidney injury molecule-1 suggests early progressive renal decline in non-proteinuric patients with type 1 diabetes. Kidney Int. 2016, 89, 459–467. | eng |
| dcterms.references | Haase-Fielitz, A.; Bellomo, R.; Devarajan, P.; Story, D.; Matalanis, G.; Dragun, D.; Haase, M. Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery—A prospective cohort study. Crit. Care Med. 2009, 37, 553–560. | eng |
| dcterms.references | Kaul, A.; Behera, M.R.; Rai, M.K.; Mishra, P.; Bhaduaria, D.S.; Yadav, S.; Agarwal, V.; Karoli, R.; Prasad, N.; Gupta, A.; et al. Neutrophil Gelatinase-associated Lipocalin: As a Predictor of Early Diabetic Nephropathy in Type 2 Diabetes Mellitus. Indian J. Nephrol. 2018, 28, 53–60. | eng |
| dcterms.references | Barutta, F.; Bellini, S.; Canepa, S.; Durazzo, M.; Gruden, G. Novel biomarkers of diabetic kidney disease: Current status and potential clinical application. Acta Diabetol. 2021, 58, 819–830. | eng |
| dcterms.references | DeFronzo, R.A.; Reeves, W.B.; Awad, A.S. Pathophysiology of diabetic kidney disease: Impact of SGLT2 inhibitors. Nat. Rev. Nephrol. 2021, 17, 319–334. | eng |
| dcterms.references | Tye, S.C.; Denig, P.; Heerspink, H.J.L. Precision medicine approaches for diabetic kidney disease: Opportunities and challenges. Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc.-Eur. Ren. Assoc. 2021, 36 (Suppl. S2), 3–9. | eng |
| dcterms.references | Gupta, A.; Singh, K.; Fatima, S.; Ambreen, S.; Zimmermann, S.; Younis, R.; Krishnan, S.; Rana, R.; Gadi, I.; Schwab, C.; et al. Neutrophil Extracellular Traps Promote NLRP3 Inflammasome Activation and Glomerular Endothelial Dysfunction in Diabetic Kidney Disease. Nutrients 2022, 14, 2965. | eng |
| dcterms.references | Panduru, N.M.; Forsblom, C.; Saraheimo, M.; Thorn, L.; Bierhaus, A.; Humpert, P.M.; Groop, P.-H. Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 2013, 36, 2077–2083. | eng |
| dcterms.references | Kalantarinia, K.; Awad, A.S.; Siragy, H.M. Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. Kidney Int. 2003, 64, 1208–1213. | eng |
| dcterms.references | Pavkov, M.E.; Nelson, R.G.; Knowler,W.C.; Cheng, Y.; Krolewski, A.S.; Niewczas, M.A. Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes. Kidney Int. 2015, 87, 812–819. | eng |
| dcterms.references | Sanchez, M.; Roussel, R.; Hadjadj, S.; Moutairou, A.; Marre, M.; Velho, G.; Mohammedi, K. Plasma concentrations of 8-hydroxy- 20-deoxyguanosine and risk of kidney disease and death in individuals with type 1 diabetes. Diabetologia 2018, 61, 977–984. | eng |
| dcterms.references | Samsu, N. Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment. BioMed Res. Int. 2021, 2021, 1497449. | eng |
| dcterms.references | Rico Fontalvo, J.E. Diabetic kidney disease: From face to prevention, diagnosis and early intervention. Rev. Colomb. Nefrol. 2020, 7, 15–16. | eng |
| dcterms.references | Vargas, J.M.L.; Fontalvo, J.E.R.; Rojas, E.M.; Barrios, G.A.C.; Rincón, A.R.; Gomez, A.M.; Martinez, S.; Bernal, L. Effect of pharmacological therapies for glycemic control in patients with type 2 diabetes mellitus on vascular outcomes. Rev. Colomb. Nefrol. 2020, 7, 44–59. | eng |
| dcterms.references | Satirapoj, B. Tubulointerstitial Biomarkers for Diabetic Nephropathy. J. Diabetes Res. 2018, 2018, 2852398. | eng |
| dcterms.references | Satirapoj, B.; Adler, S.G. Comprehensive approach to diabetic nephropathy. Kidney Res. Clin. Pract. 2014, 33, 121–131. | eng |
| dcterms.references | Satirapoj, B.; Adler, S.G. Prevalence and Management of Diabetic Nephropathy in Western Countries. Kidney Dis. 2015, 1, 61–70. | eng |
| dcterms.references | Satirapoj, B.; Nast, C.C.; Adler, S.G. Novel insights into the relationship between glomerular pathology and progressive kidney disease. Adv. Chronic Kidney Dis. 2012, 19, 93–100. | eng |
| dcterms.references | Ostermann, M.; Zarbock, A.; Goldstein, S.; Kashani, K.; Macedo, E.; Murugan, R.; Bell, M.; Forni, L.; Guzzi, L.; Joannidis, M.; et al. Recommendations on Acute Kidney Injury Biomarkers from the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement. JAMA Netw. Open 2020, 3, e2019209. | eng |
| dcterms.references | Forsblom, C.; Moran, J.; Harjutsalo, V.; Loughman, T.; Wadén, J.; Tolonen, N.; Thorn, L.; Saraheimo, M.; Gordin, D.; Groop, P.H.; et al. Added value of soluble tumor necrosis factor-x receptor 1 as a biomarker of ESRD risk in patients with type 1 diabetes. Diabetes Care 2014, 37, 2334–2342. | eng |
| dcterms.references | Andrésdóttir, G.; Jensen, M.L.; Carstensen, B.; Parving, H.H.; Hovind, P.; Hansen, T.W.; Rossing, P. Improved prognosis of diabetic nephropathy in type 1 diabetes. Kidney Int. 2015, 87, 417–426. | eng |
| dcterms.references | Thipsawat, S. Early detection of diabetic nephropathy in patients with type 2 diabetes mellitus: A review of the literature. Diabetes Vasc. Dis. Res. 2021, 18, 14791641211058856. | eng |
| dcterms.references | Turk, V.; Stoka, V.; Vasiljeva, O.; Renko, M.; Sun, T.; Turk, B.; Turk, D. Cysteine cathepsins: From structure, function, and regulation to new frontiers. Biochim. Biophys. Acta 2012, 1824, 68–88. | eng |
| dcterms.references | Shi, G.P.; Sukhova, G.K.; Grubb, A.; Ducharme, A.; Rhode, L.H.; Lee, R.T.; Ridker, P.M.; Libby, P.; Chapman, H.A. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J. Clin. Investig. 1999, 104, 1191–1197. | eng |
| dcterms.references | Xu, Y.; Ding, Y.; Li, X.; Wu, X. Cystatin C is a disease-associated protein subject to multiple regulation. Immunol. Cell Biol. 2015, 93, 442–451. | eng |
| dcterms.references | Dharnidharka, V.R.; Kwon, C.; Stevens, G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. Am. J. Kidney Dis. Off. J. Natl. Kidney Found. 2002, 40, 221–226. | eng |
| dcterms.references | Herget-Rosenthal, S.; Marggraf, G.; Hüsing, J.; Göring, F.; Pietruck, F.; Janssen, O.; Phillip, T.; Kribben, A. Early detection of acute renal failure by serum cystatin, C. Kidney Int. 2004, 66, 1115–1122. | eng |
| dcterms.references | Ling, W.; Zhaohui, N.; Ben, H.; Leyi, G.; Jianping, L.; Huili, D.; Jiaqi, Q. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. Nephron Clin. Pract. 2008, 108, c176–c181. | eng |
| dcterms.references | Kim, S.S.; Song, S.H.; Kim, I.J.; Jeon, Y.K.; Kim, B.H.; Kwak, I.S.; Lee, E.K.; Kim, Y.K. Urinary cystatin C and tubular proteinuria predict progression of diabetic nephropathy. Diabetes Care 2013, 36, 656–661. | eng |
| dcterms.references | Jeon, Y.L.; Kim, M.H.; Lee, W.I.; Kang, S.Y. Cystatin C as an early marker of diabetic nephropathy in patients with type 2 diabetes. Clin. Lab. 2013, 59, 1221–1229. | eng |
| dcterms.references | Abbasi, F.; Moosaie, F.; Khaloo, P.; Dehghani Firouzabadi, F.; Fatemi Abhari, S.M.; Atainia, B.; Ardeshir, M.; Nakhjavani, M.; Esteghamati, A. Neutrophil Gelatinase-Associated Lipocalin and Retinol-Binding Protein-4 as Biomarkers for Diabetic Kidney Disease. Kidney Blood Press. Res. 2020, 45, 222–232. | eng |
| dcterms.references | Nauta, F.L.; Boertien,W.E.; Bakker, S.J.L.; van Goor, H.; van Oeveren,W.; de Jong, P.E.; Bilo, H.; Gansevoort, R. Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care 2011, 34, 975–981. | eng |
| dcterms.references | de Carvalho, J.A.M.; Tatsch, E.; Hausen, B.S.; Bollick, Y.S.; Peres,W.; Duarte, M.M.M.F. Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as indicators of tubular damage in normoalbuminuric patients with type 2 diabetes. Clin. Biochem. 2016, 49, 59–64. | eng |
| dcterms.references | He, P.; Bai, M.; Hu, J.P.; Dong, C.; Sun, S.; Huang, C. Significance of Neutrophil Gelatinase-Associated Lipocalin as a Biomarker for the Diagnosis of Diabetic Kidney Disease: A Systematic Review and Meta-Analysis. Kidney Blood Press Res. 2020, 45, 497–509. | eng |
| dcterms.references | Sabbisetti, V.S.; Waikar, S.S.; Antoine, D.J.; Smiles, A.; Wang, C.; Ravisankar, A.; Ito, K.; Sharma, S.; Ramadesikan, S.; Lee, M.; et al. Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J. Am. Soc. Nephrol. 2014, 25, 2177–2186. | eng |
| dcterms.references | de Zeeuw, D. The future of Diabetic Kidney Disease management: Reducing the unmet need. J. Nephrol. 2020, 33, 1163–1169. | eng |
| dcterms.references | Rico-Fontalvo, J.; Daza-Arnedo, R.; Cardona-Blanco, M.X.; Leal-Martínez, V.; Abuabara-Franco, E.; Pajaro-Galvis, N.; Cabrales, J.; Correa, J.; Cueto, M.; Duran, A.; et al. SGLT2 Inhibitors and nephroprotection in diabetic kidney disease: From mechanisms of action to the latest evidence in the literature. J. Clin. Nephrol. 2020, 4, 44–55. | eng |
| dcterms.references | Petrykiv, S.I.; Laverman, G.D.; de Zeeuw, D.; Heerspink, H.J.L. The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients. Diabetes Obes. Metab. 2017, 19, 1363–1370. | eng |
| dcterms.references | Cefalu, W.T.; Leiter, L.A.; Yoon, K.H.; Arias, P.; Niskanen, L.; Xie, J.; Balis, D.; Canovatchel,W.; Meininger, G. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52-week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013, 382, 941–950. | eng |
| dcterms.references | Heerspink, H.J.L.; Perco, P.; Mulder, S.; Leierer, J.; Hansen, M.K.; Heinzel, A.; Mayer, G. Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia 2019, 62, 1154–1166. | eng |
| dcterms.references | Sen, T.; Li, J.; Neuen, B.L.; Neal, B.; Arnott, C.; Parikh, C.R.; Coca, S.; Perkovic, V.; Mahaffey, K.; Yavin, Y.; et al. Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial. Diabetologia 2021, 64, 2147–2158. | eng |
| dcterms.references | Bletsa, E.; Filippas-Dekouan, S.; Kostara, C.; Dafopoulos, P.; Dimou, A.; Pappa, E.; Chasapi, S.; Spyroulias, G.; Koutsovasilis, A.; Bairaktari, E.; et al. Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes. J. Clin. Endocrinol. Metab. 2021, 106, 1269–1283. | eng |
| dcterms.references | Navarro-González, J.F.; Mora-Fernández, C.; Muros de Fuentes, M.; Chahin, J.; Méndez, M.L.; Gallego, E.; Macia, M.; Nieves del Castillo, A.; Getino, M.; Garcia, P.; et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: The PRE-DIAN trial. J. Am. Soc. Nephrol. 2015, 26, 220–229. | eng |
| dcterms.references | Rico, J.E.; Daza Anedo, R.; Raad Sarabia, M.; Pájaro Galvis, N.; Bello Espinosa, A.; Isabella Pérez Calvo, C.; Pomares Lara, A.; Mondol Almeida, Z.; Vergara Serpa, O.; Berrocal Martinez, C.; et al. Urinary proteome in diabetic kidney disease: State of the art: Proteoma urinario en la enfermedad renal diabética. Estado Arte Rev. Colomb. Nefrol. 2021, 8, e546. | eng |
| dcterms.references | Lindhardt, M.; Persson, F.; Zürbig, P.; Stalmach, A.; Mischak, H.; de Zeeuw, D.; Lambers Heerspink, H.; Klein, R.; Orchard, T.; Porta, M.; et al. Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. Nephrol. Dial. Transplant. 2017, 32, 1866–1873. | eng |
| dcterms.references | Tofte, N.; Lindhardt, M.; Adamova, K.; Bakker, S.J.L.; Beige, J.; Beulens, J.W.J.; Birkenfeld, A.; Currie, G.; Delles, C.; Dimons, I.; et al. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): A prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes Endocrinol. 2020, 8, 301–312. | eng |
| dcterms.references | Siwy, J.; Klein, T.; Rosler, M.; von Eynatten, M. Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase-4 Inhibition: A Hypothesis-Generating Analysis from the MARLINA-T2D Trial. Proteom. Clin. Appl. 2019, 13, e1800144. | eng |
| dcterms.references | Coca, S.G.; Nadkarni, G.N.; Huang, Y.; Moledina, D.G.; Rao, V.; Zhang, J.; Ferket, B.; Crowley, S.; Fried, L.; Parik, C. Plasma Biomarkers and Kidney Function Decline in Early and Established Diabetic Kidney Disease. J. Am. Soc. Nephrol. 2017, 28, 2786–2793. | eng |
| dcterms.references | Schrauben, S.J.; Shou, H.; Zhang, X.; Anderson, A.H.; Bonventre, J.V.; Chen, J.; Coca, S.; Furth, S.; Greenberg, J.; Gutierrez, O.; et al. Association of multiple plasma biomarker concentrations with progression of prevalent diabetic kidney disease: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. J. Am. Soc. Nephrol. 2021, 32, 115–126. | eng |
| dcterms.references | Elmarakby, A.A.; Sullivan, J.C. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc. Ther. 2012, 30, 49–59. | eng |
| dcterms.references | Hasegawa, G.; Nakano, K.; Sawada, M.; Uno, K.; Shibayama, Y.; Ienaga, K.; Kondo, M. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int. 1991, 40, 1007–1012. | eng |
| dcterms.references | Bertani, T.; Abbate, M.; Zoja, C.; Corna, D.; Perico, N.; Ghezzi, P.; Remuzzi, G. Tumor necrosis factor induces glomerular damage in the rabbit. Am. J. Pathol. 1989, 134, 419–430. | eng |
| dcterms.references | Krolewski, A.S.; Niewczas, M.A.; Skupien, J.; Gohda, T.; Smiles, A.; Eckfeldt, J.H.; Doria, A.; Warram, J. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care 2014, 37, 226–234. | eng |
| dcterms.references | Gohda, T.; Niewczas, M.A.; Ficociello, L.H.; Walker, W.H.; Skupien, J.; Rosetti, F.; Cullere, X.; Johnson, A.; Crabtree, G.; Smiles, A.; et al. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J. Am. Soc. Nephrol. 2012, 23, 516–524. | eng |
| dcterms.references | Looker, H.C.; Colombo, M.; Hess, S.; Brosnan, M.J.; Farran, B.; Dalton, R.N.; Wong, M.; Turner, C.; Palmer, C.; Nogoceke, E.; et al. Biomarkers of rapid chronic kidney disease progression in type 2 diabetes. Kidney Int. 2015, 88, 888–896. | eng |
| dcterms.references | Lopes-Virella, M.F.; Baker, N.L.; Hunt, K.J.; Cleary, P.A.; Klein, R.; Virella, G. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care 2013, 36, 2317–2323. | eng |
| dcterms.references | Skupien, J.; Warram, J.H.; Niewczas, M.A.; Gohda, T.; Malecki, M.; Mychaleckyj, J.C.; Galecki, A.; Krowleski, A. Synergism between circulating tumor necrosis factor receptor 2 and HbA(1c) in determining renal decline during 5-18 years of follow-up in patients with type 1 diabetes and proteinuria. Diabetes Care 2014, 37, 2601–2608. | eng |
| dcterms.references | Gutiérrez, O.M.; Shlipak, M.G.; Katz, R.; Waikar, S.S.; Greenberg, J.H.; Schrauben, S.J.; Coca, S.; Parikh, C.; Vasan, R.; Feldman, H.; et al. Associations of plasma biomarkers of inflammation, fibrosis, and kidney tubular injury with progression of diabetic kidney disease: A cohort study. Am. J. Kidney Dis. 2022, 79, 849–857.e1. | eng |
| dcterms.references | Wu, L.L.; Chiou, C.C.; Chang, P.Y.;Wu, J.T. Urinary 8-OHdG: A marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin. Chim. Acta Int. J. Clin. Chem. 2004, 339, 1–9. | eng |
| dcterms.references | Xu, G.W.; Yao, Q.H.;Weng, Q.F.; Su, B.L.; Zhang, X.; Xiong, J.H. Study of urinary 8-hydroxydeoxyguanosine as a biomarker of oxidative DNA damage in diabetic nephropathy patients. J. Pharm. Biomed. Anal. 2004, 36, 101–104. | eng |
| dcterms.references | Serdar, M.; Sertoglu, E.; Uyanik, M.; Tapan, S.; Akin, K.; Bilgi, C.; Kurt, I. Comparison of 8-hydroxy-20-deoxyguanosine (8-OHdG) levels using mass spectrometer and urine albumin creatinine ratio as a predictor of development of diabetic nephropathy. Free Radic. Res. 2012, 46, 1291–1295. | eng |
| dcterms.references | Yoon, S.Y.; Kim, J.S.; Jeong, K.H.; Kim, S.K. Acute Kidney Injury: Biomarker-Guided Diagnosis and Management. Medicina 2022, 58, 340. | eng |
| dcterms.references | Schrezenmeier, E.V.; Barasch, J.; Budde, K.;Westhoff, T.; Schmidt-Ott, K.M. Biomarkers in acute kidney injury—Pathophysiological basis and clinical performance. Acta Physiol. 2017, 219, 554–572. | eng |
| dcterms.references | Coca, S.G.; Yalavarthy, R.; Concato, J.; Parikh, C.R. Biomarkers for the diagnosis and risk stratification of acute kidney injury: A systematic review. Kidney Int. 2008, 73, 1008–1016. | eng |
| dcterms.references | Bell, M.; Larsson, A.; Venge, P.; Bellomo, R.; Mårtensson, J. Assessment of cell-cycle arrest biomarkers to predict early and delayed acute kidney injury. Dis. Markers 2015, 2015, 158658. | eng |
| dcterms.references | Hasson, D.; Menon, S.; Gist, K.M. Improving acute kidney injury diagnostic precision using biomarkers. Pract. Lab. Med. 2022, 30, e00272. | eng |
| oaire.version | info:eu-repo/semantics/publishedVersion | spa |